Normal HLA class I, II, and MICA gene distribution in uveal melanoma. by Metzelaar-Blok, J.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/48983
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
 Molecular Vision 2005; 11:1166-72 <http://www.molvis.org/molvis/v11/a134/>
Received 4 April 2005 | Accepted 14 December 2005 | Published 21 December 2005
 The human leukocyte antigen (HLA) complex, located
on chromosome 6, plays an important role in the cellular im-
mune response to tumor antigens. The function of cytotoxic T
lymphocytes (CTLs) and of natural killer (NK) cells is di-
rectly influenced by expression of HLA antigens on tumor
cells [1-3]. Many types of tumors use downregulation of HLA
expression as an effective mechanism to escape immune sur-
veillance [1,4]. NK cells on the other hand are able to kill
tumor cells that have lost their specific HLA class I cell-sur-
face molecules. The most successful tumor cells are those cells
that downregulate HLA in such a way that they are not recog-
nized by specific CTLs but still have sufficient HLA expres-
sion to avoid NK cells. Uveal melanoma cells, however, are
in this matter completely different from most other tumors. In
uveal melanoma, downregulation of HLA class I is not asso-
ciated with tumor cell escape and disease progression, but with
a favorable patient outcome [5,6]. This suggests that NK cells
play a protective role in the development of metastatic dis-
ease by killing tumor cells with a low HLA class I expression.
In addition, not only expression of HLA class I, but also ex-
pression of HLA class II was found to be related to a worse
survival in uveal melanoma [6].
The outstanding feature of the HLA genes is their exten-
sive polymorphism. This polymorphism defines the repertoire
of (tumor-derived) peptides that bind to HLA allotypes and
subsequently influences the activation of specific CTLs. In
the literature, a relatively small, but growing number of stud-
ies indicates that, apart from the quantitative level of HLA
expression, also HLA polymorphisms mediate susceptibility
to several neoplastic diseases [7,8]. In nonmelanoma skin can-
cer, HLA-A3, HLA-B27, and HLA-DR7 have been associ-
ated with an increased risk of developing disease, whereas
HLA-A11 and HLA-DR4 were associated with a decreased
risk [9,10]. The presence of HLA-B40 was observed to be
related to both the development and the clinical progression
of cutaneous melanoma [11]. In uveal melanoma, associations
with certain HLA class I and II antigens have been described,
too. However, the findings are contradictory, with the excep-
tion for a significantly increased incidence of HLA-A32 in
two studies [12-15]. Similar to the situation in cutaneous mela-
noma, the presence of HLA-B40 was correlated with poor
survival in uveal melanoma patients [16].
Recently, a new family of HLA class I-like molecules has
been identified, MHC class I chain-related gene A (MICA)
[17,18], located approximately 50 kb centromeric to the HLA-
B gene. Similarly to the HLA class I genes, the MICA gene
encodes for an α chain with three extracellular domains (a1,
a2, and a3), a transmembrane segment, and a cytoplasmic tail.
However, MICA is highly divergent from the other HLA class
I molecules: MICA proteins lack a CD8 binding site; they do
not associate with β2 microglobulin and do not need to be
stabilized by peptide binding. MICA molecules are frequently
expressed on monocytes, endothelial cells, epithelial cells, fi-
broblasts, and keratinocytes [19]. Expression of MICA has
been described for several epithelial tumors [20] and for cuta-
neous melanoma [21]. As MICA expression is upregulated
after heat shock treatment, MICA molecules are considered to
play a role in the immunological elimination of stress-induced
damaged cells [18,22,23]. Recently, MIC-A/B expression was
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observed on 50% of primary uveal melanomas [24]. It was
not expressed on most metastatic lesions. Yet there was one
intriguing case: A subcutaneous metastasis taken from a pa-
tient prior to chemotherapy showed no MIC-A/B expression;
however, following treatment with systemic fotemustine, a
second metastasis was removed. This metastasis showed a
positive MIC-A/B expression and an abundant infiltrate with
NKG2D positive lymphocytes. Since MICA activates immune
cells via the NKG2D receptor, expressed on γδ T cells, CD8
αβ T cells, and NK cells, this suggests that chemotherapy may
lead to phenotypical changes which stimulate immunological
surveillance, helping the removal of transformed, infected, or
damaged cells, and that MIC-A/B may be involved in this pro-
cess [22,25].
Associations between MIC genes and several types of
cancer have been described: In cervical intraepithelial neo-
plasia and nonmelanoma skin cancer, this polymorphism was
not associated with an increased cancer risk, while in breast
cancer a certain extended haplotype that included MICA was
associated with an increased risk of developing this malig-
nancy [26-28]. In oral squamous cell carcinoma, an increase
of the MICA A6 allele frequency was observed, while in gas-
tric cancer an association with the genetically determined pres-
ence of MICA type A9 was observed [29,30]. In uveal mela-
noma, to our best knowledge, MICA polymorphism has not
yet been investigated.
The aim of the present study was to examine the role of
HLA class I, class II, and MICA polymorphism in uveal mela-
noma. Early studies on this topic, presenting contradictory
results [12-15], may be outdated due to low patient numbers,
limited number of HLA antigens tested, and a less accurate
determination of HLA type. In addition, during the last de-
cade, the introduction of molecular HLA typing methods re-
sulted in a better definition and characterization of specific
HLA antigens and alleles. We set out to determine if a suscep-
tibility gene or a protective gene for uveal melanoma is lo-
cated among the HLA class I or II region or within the MICA
genes. Therefore, we determined the HLA-A, HLA-B, HLA-
C, HLA-DR, HLA-DQ, and MICA allele distribution in, re-
spectively, 159 and 168 Dutch uveal melanoma patients in
comparison to a large panel of healthy Dutch individuals.
METHODS
HLA-typed patients and controls:  Between 1999, and 2001,
159 consecutive Dutch patients diagnosed with primary chor-
oidal and/or ciliary body melanoma at the Department of Oph-
thalmology of the Leiden University Medical Center (LUMC)
were typed for HLA class I and II, either by a complement-
dependent cytotoxicity test (60 patients) or by DNA-based
techniques (99 patients). Of the 159 patients, 92 were women
and 67 were men. Age range was 26-84 years, with a mean
age at diagnosis of 60.85 years. Sixty-six of these patients
were treated by enucleation. The other patients received ru-
thenium brachytherapy in combination with transpupillary
thermotherapy. The control group consisted of 2,440 healthy
Dutch blood donors. For this group, the HLA gene frequen-
cies are extensively analyzed and well controlled. This group
is considered to be an excellent representation of the HLA
gene distribution in the Dutch population [31].
MICA-typed patients and controls:  The 168 uveal mela-
noma patients analyzed for MICA gene variants visited the
Department of Ophthalmology of the LUMC between April
1998 and March 1999. All patients, 73 male and 95 female,
were diagnosed as having primary choroidal and/or ciliary
body melanoma at the age of 7-82 years, with a mean age of
58.96 years. Twenty-one of these patients were treated by
enucleation. The other patients received ruthenium
brachytherapy in combination with transpupillary thermo-
therapy. The MICA-typed population shared 114 patients with
the HLA-typed group (see Figure 1). The control group of
247 healthy persons was recruited from the Ophthalmology
Outpatient Clinic of the LUMC. Exclusion criteria were the
xeroderma pigmentosum (XP) syndrome, presence of cutane-
ous melanoma, and being non-Caucasian. This control group
has been used in several LUMC cancer studies [27,32]. In
both studies the research protocol followed the tenets of the
Declaration of Helsinki.
HLA-typing:  Sixty patients were typed for HLA class I
(A, B, C) and II (DR, DQ) by complement-dependent cyto-
toxicity test. In the remaining 99 patients, HLA-genotyping
was performed on genomic DNA, isolated from peripheral
blood leukocytes by ARMS PCR.
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Figure 1. Composition of study popula-
tions.  The HLA-typed study group con-
sisted of 159 uveal melanoma patients,
of which 66 were enucleated. The MHC
class I chain-related gene A (MICA)-
typed study group consisted of 168 uveal
melanoma patients, of which 21 were
enucleated.
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MICA-microsatellite typing:  Genomic DNA from 168
uveal melanoma patients was extracted from peripheral blood
leukocytes and adjusted to 100 ng/µl. The following primers
were used: flanking primer, MICA forward 5F 5'-CCT TTT
TTT CAG GGA AAG TGC-3'; reverse MICA 5R 5'-CCT TAC
CAT CTT CCA GAA ACT GC-3'. The 5F primer was labeled
with fluorescent amadite (Isogen Bioscience, Maarssen, The
Netherlands). The forward primer corresponds to the bound-
ary region with 12 nucleotides in intron 4, whereas the re-
verse primer is located in intron 5 of the transmembrane re-
gion.
The amplification was performed in 50 µl reaction vol-
ume containing 1 µl genomic DNA, 25 pmol of each primer,
2.5 units Taq Polymerase (Perkin Elmer Nieuwerkerk a/d
IJssel, the Netherlands). The amplification buffer contained
50 mM KCl, 10 mmol Tris-HCl (pH 8.4, at room tempera-
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TABLE 1. DISTRIBUTION OF HLA-A, HLA-B, AND HLA-C ANTIGENS IN UVEAL MELANOMA PATIENTS AND HEALTHY DUTCH BLOOD DONORS
               Uveal melanoma          Dutch blood
              patients (n=159)       donors (n=2440)
             -------------------   -------------------
              Number    Percent     Number    Percent    Odds        p             p
HLA allele   positive   positive   positive   positive   ratio   uncorrected   corrected
----------   --------   --------   --------   --------   -----   -----------   ---------
A1              50         31         747        31      1.044     0.8592       1.0000
A2              88         55        1284        53      1.114     0.5132       1.0000
A3              37         23         700        29      0.760     0.1473       1.0000
A11             16         10         281        12      0.880     0.6994       1.0000
A23 (A9)         4          3          60         2      1.132     1.0000       1.0000
A24 (A9)        36         23         403        17      1.481     0.0630       0.9970
A25 (A10)        5          3          46         2      1.832     0.2375       1.0000
A26 (A10)        8          5         107         4      1.218     0.6889       1.0000
A28              9          6         244        10      0.566     0.0735       0.9989
A29 (A19)        7          4         119         5      0.955     1.0000       1.0000
A30 (A19)        5          3          85         3      0.979     1.0000       1.0000
A31 (A19)       11          7         146         6      1.211     0.6060       1.0000
A32 (A19)        7          4         149         6      0.753     0.4903       1.0000
A33 (A19)        2          1          32         1      1.174     1.0000       1.0000
B5              21         13         289        12      1.154     0.6131       1.0000
B7              37         23         668        27      0.812     0.2710       1.0000
B8              43         27         554        23      1.270     0.2069       1.0000
B12             36         23         617        25      0.872     0.5092       1.0000
B13             10          6         109         4      1.495     0.3230       1.0000
B14              4          3          70         3      0.972     1.0000       1.0000
B17             14          9         162         7      1.397     0.3257       1.0000
B18             15          9         158         6      1.545     0.1412       1.0000
B21              2          1          54         2      0.694     0.5791       1.0000
B27             12          8         157         6      1.229     0.6168       1.0000
B35             25         16         429        18      0.887     0.5916       1.0000
B37              2          1          99         4      0.373     0.0880       0.9997
B38 (B16)        7          4          98         4      1.169     0.8340       1.0000
B39 (B16)        9          6          79         3      1.873     0.1104       1.0000
B41              3          2          28         1      1.892     0.4338       1.0000
B55 (B22)        7          4         105         4      1.085     0.8422       1.0000
B56 (B22)        3          2          33         1      1.601     0.4826       1.0000
B60 (B40)       16         10         361        15      0.659     0.1045       0.9999
B61 (B40)        5          3          73         3      1.132     0.8130       1.0000
B62 (B15)       29         18         370        15      1.263     0.3065       1.0000
B63 (B15)        2          1          12         0      3.079     0.2101       1.0000
CW1             12          8         119         5      1.550     1.1990       1.0000
CW2             15          9         240        10      0.919     0.7884       1.0000
CW3             44         28         795        35      0.728     0.0836       0.9996
CW4             31         19         514        22      0.855     0.4889       1.0000
CW5             22         14         312        14      1.034     0.9053       1.0000
CW6             28         18         373        17      1.026     0.9141       1.0000
CW7             93         58        1102        51      1.344     0.0840       0.9996
The “p corrected” column represents the correction of p values for the number of comparisons (93) conducted according to the method of
Edwards [35].
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ture), 2 mM MgCl2, 1.25% glycerol, and 200 µM of each
dNTPs. The amplification was performed in two steps to in-
crease the specificity of primer annealing during the first 8
cycles on a Peltier Thermal Cycler (PTC-200 MJ research).
The PCR was carried out as a touch down amplification. The
reaction mixture was subjected to one cycle of denaturation at
95 °C for 5 min followed by 8 cycles of denaturation at 94 °C
for 30 s, and the annealing temperature of 68 °C was decreased
by 1 °C per cycle in the first 8 cycles. Extension was per-
formed at 72 °C for 30 s. After the 8 cycles the amplification
was done for 30 cycles at 94 °C for 30 s, annealing at 60 °C
for 30 s and extension at 72 °C for 30 s. Finally, the PCR was
finished by an extension at 72 °C for 5 min. The PCR prod-
ucts were visualized on 2% agarose gels.
For accurate allele sizing, four internal allelic ladders and
two external size markers covering the range of the MICA
microsatellites were used. The reaction product was loaded
into the wells of a standard denaturing sequencing gel (6.0%
polyacrylamide, 0.6X TBE, 280x30x0.5 mm) in an Automated
Laser Fluorescence-DNA Sequencer (ALF™, Amersham
Pharmacia Biotech, Roosendaal, the Netherlands). Electro-
phoresis (2000 V, 50 mA, 50 W, and 3 mW laser power at 50
°C) and data collection was carried out using the ALF Man-
ager software (Amersham Pharmacia Biotech). The data were
analyzed by Fragment Manager software (Amersham
Pharmacia Biotech).
Statistical analysis:  The significance of differences in
the HLA antigen frequencies in uveal melanoma patients com-
pared to the control population was assessed using the Woolf-
Haldane analysis [33,34]. Correction of p values for the num-
ber of comparisons (93) was done using the method of Edwards
[35]. Odds ratios were calculated as an estimation of the rela-
tive risks. Data were further analyzed using an exact (strati-
fied) 2x2 analysis and by stepwise logistic regression (multi-
variate analysis).
Fisher’s exact test was used to compare MICA allele fre-
quencies in uveal melanoma patients and healthy controls. To
correct for the number of comparisons, the p values were mul-
tiplied by five (number of MICA alleles).
RESULTS
Distribution of HLA class I and II alleles:  The frequencies of
HLA class I (A, B, C) and class II (DR, DQ) alleles were
analyzed in 159 Dutch uveal melanoma patients and in 2440
healthy Dutch individuals. In total, 93 different alleles (in-
cluding the split antigens) were determined. A tendency (p<0.1)
for an increased allele frequency in uveal melanoma patients
was observed for HLA-A24 and HLA-Cw7, while the fre-
quencies of HLA-A28, HLA-B37, HLA-Cw3, and HLA-DQ5
tended to be decreased (Table 1, Table 2). The HLA-DQ4 al-
lele was significantly decreased (p=0.0129) in the patient
group, but the number of healthy individuals tested for this
antigen was only 915. However, after correction for the num-
ber of comparisons, the p value was close to 1.00 for all HLA
alleles. Also in the multivariate analysis, no significances were
found. In Table 1 and Table 2, the distribution of the HLA
antigens is summarized.
We also analyzed the presence of certain HLA class I or
II alleles in relation to several clinicopathological parameters
(e.g., cell type, tumor diameter, prominence, mitotic rate, pres-
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TABLE 2. DISTRIBUTION OF HLA-DR AND HLA-DQ ANTIGENS IN UVEAL MELANOMA PATIENTS AND HEALTHY DUTCH BLOOD DONORS
               Uveal melanoma           Dutch blood
              patients (n=159)       donors (n=2440)
             -------------------   -------------------
              Number    Percent     Number    Percent    Odds         p            p
HLA allele   positive   positive   positive   positive   Ratio   uncorrected   corrected
----------   --------   --------   --------   --------   -----   -----------   ---------
DR1             24         15        473          20     0.734     0.1782       1.0000
DR3             46         29        599          25     1.228     0.2995       1.0000
DR4             44         28        679          28     0.974     0.9276       1.0000
DR7             33         21        459          19     1.117     0.6044       1.0000
DR8             13          8        128           5     1.624     0.1483       1.0000
DR10             4          3        100           4     0.661     0.4074       1.0000
DR11 (DR5)      21         13        340          14     0.937     0.8145       1.0000
DR12 (DR5)       5          3        108           5     0.743     0.5508       1.0000
DR13 (DR6)      48         30        669          28     1.096     0.6502       1.0000
DR14 (DR6)       9          6        127           5     1.094     0.8566       1.0000
DR15 (DR2)      47         30        414*         26     1.231     0.2964       1.0000
DR16 (DR2)       3          2         43           2     1.177     1.0000       1.0000
DQ2             64         40        881        1479     1.134     0.4985       1.0000
DQ4             12          8         29*          3     2.547     0.0129       0.6856
DQ5 (DQ1)       39         25        300*         35     0.619     0.0132       0.6945
DQ6 (DQ1)       83         52        453*         50     1.087     0.6674       1.0000
DQ7 (DQ3)       40         25        652          28     0.877     0.5216       1.0000
DQ8 (DQ3)       27         17        184*         20     0.817     0.3882       1.0000
DQ9 (DQ3)       14          9         71*          8     1.177     0.6340       1.0000
The “p corrected” column represents the correction of p values for the number of comparisons (93) conducted according to the method of
Edwards [35]. The asterisk (*) indicates that the number of healthy individuals typed for this specific allele is fewer than 2,440.
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ence of vascular loops) of 64 uveal melanomas obtained by
enucleation. After correction for the number of comparisons,
no significant associations were present (data not shown).
Distribution of MICA gene variants:  As MICA associa-
tions have been found with regard to other malignancies, we
wondered whether any MICA antigen occurred more fre-
quently in uveal melanoma patients.
The MICA allele frequencies were determined in 168
uveal melanoma patients and 247 healthy controls (Table 3).
Triplet repeat polymorphisms in the transmembrane region
identified as A4, A5, A5.1, A6, and A9 were evaluated in both
groups. Compared to the other alleles, the A5.1 allele was the
most common allele present. The MICA A5 allele frequency
was significantly decreased in the patient group (p=0.030).
However, after correction of the p value for the number of
comparisons, this difference was no longer significant (Table
3). Between the two groups, no other significant differences
were observed, suggesting that MICA gene polymorphism is
not associated with an increased risk for the occurrence of
uveal melanoma.
DISCUSSION
 In the present study, we examined the role of HLA class I
polymorphism in uveal melanoma. A direct disease associa-
tion with a specific HLA allele suggests that the function of
the HLA molecule encoded by this allele may differ signifi-
cantly from the molecules encoded by alternative alleles in its
ability to present tumor antigens to T lymphocytes [8]. There-
fore, it is not surprising that numerous associations have been
established between HLA type and immune-mediated diseases.
Also in cancer, a relatively small number of studies have es-
tablished HLA-related susceptibility [7,8]. However, in these
publications relative risks are low, even for virally associated
cancers, such as cervical neoplasia (human papillomavirus)
and Hodgkin’s lymphoma (Epstein-Barr virus) [7,8,36,37]. In
a number of studies, associations found between HLA type
and cancer lack significance after correction of the p value for
the number of antigens studied [11,13,14,38]. Our study on
HLA polymorphisms and uveal melanoma contained the larg-
est number of patients tested up to now. Studying 159 uveal
melanoma patients and 2,440 healthy Dutch blood donors, we
did not find any significant HLA associations. This is in agree-
ment with a previous study by Völker-Dieben et al. [14], but
in contrast with two other studies that described an increased
frequency of HLA-A32 [13,15]. In our study, the frequency
of HLA-A32 was low (4% in the patient group and 6% in the
control group) with no significant difference (uncorrected
p=0.4903, Table 1). It should be noted again that direct com-
parison of these studies is complicated because of differences
in sample sizes, experimental designs, statistical analyses,
composition of control groups and improved laboratory meth-
ods for HLA typing.
However, these findings do not rule out an important role
for HLA class I or II in the development of metastases. An
increased expression of HLA class I is associated with a worse
prognosis, and a high HLA class I expression has been found
to inhibit NK-cell mediated lysis [5,6,39]. As NK cells ex-
press a wide range of killing receptors that recognize specific
HLA alleles only, it is most likely that when one looks specifi-
cally at such HLA alleles and survival, associations will ap-
pear.
The present study also analyzed the role of MICA poly-
morphism in uveal melanoma. A comparison of the MICA
allele distribution of 168 uveal melanoma patients with 247
healthy controls revealed no significant deviations, suggest-
ing that MICA gene polymorphisms do not contribute to the
susceptibility to develop uveal melanoma. However, this does
not exclude a possible role of MICA molecules in the pro-
gression or metastatic development of uveal melanoma. MICA
has been shown to activate NK cells via engagement of the
NKG2D receptor [22,40]. Moreover, in a recent study, resis-
tance of melanoma cell lines to NK cell-mediated lysis was
associated with a lack of MICA expression [41]. However,
MICA-triggered NK cell-mediated lysis of tumor cells can be
inhibited by co-expression of the nonclassical HLA-G mol-
ecule [40]. As already mentioned in relation to HLA class I
expression, NK cells are believed to play a protective role in
the development of metastatic disease in uveal melanoma
[5,6,42,43]. Fortunately, uveal melanoma cells do not express
HLA-G [44,45], but according to Vetter et al., primary tumors
do often express MIC-A/B [24]. MICA expression by uveal
melanoma cells may be a positive tumor characteristic because
it can provide additional stimulation of NK cells [46], and
while we did not see an association between the development
of uveal melanoma and the presence of any HLA or MICA
polymorphism, the important role of NK cells in removing
uveal melanoma metastases prior to spreading may potentially
indicate a role for polymorphisms in the formation of me-
tastases. This can only be analyzed in future studies, as death
from uveal melanoma metastases occurs quite late.
In conclusion, although HLA antigens, and possibly also
MICA antigens, are important players in the immune surveil-
lance against uveal melanoma, our data show that HLA and
MICA polymorphisms do not contribute to an increased ge-
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TABLE 3. ALLELE FREQUENCY OF THE MICA GENE IN UVEAL
MELANOMA PATIENTS AND IN HEALTHY CONTROLS
            Uveal
           melanoma       Healthy
 MICA      patients       controls
allele     (n=168)        (n=247)
------   ------------   ------------
 A4       40  (11.9%)    44   (8.9%)
 A5       23   (6.8%)    56  (11.3%)
 A5.1    172  (51.2%)   256  (51.8%)
 A6       52  (15.5%)    69  (14.0%)
 A9       49  (14.6%)    69  (14.0%)
         ------------   ------------
         336 (100%)     494 (100%)
The data in this table show that no significant differences were found
in the distribution of MICA gene variants between uveal melanoma
patients and healthy controls.
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netic susceptibility to this tumor. This does not exclude a role
for HLA antigens in the development of metastases.
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